Literature DB >> 32092979

TIPS Modification in the Management of Shunt-Induced Hepatic Encephalopathy: Analysis of Predictive Factors and Outcome with Shunt Modification.

Philipp Schindler1, Leon Seifert2, Max Masthoff1, Arne Riegel1, Michael Köhler1, Christian Wilms2, Hartmut H Schmidt2, Hauke Heinzow2, Moritz Wildgruber1,3.   

Abstract

PURPOSE: To evaluate predictive parameters for the development of Hepatic Encephalopathy (HE) after Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement and for success of shunt modification in the management of shunt-induced HE.
METHODS: A retrospective analysis of all patients with TIPS (n = 344) has been performed since 2011 in our university liver center. n = 45 patients with HE after TIPS were compared to n = 48 patients without HE after TIPS (case-control-matching). Of n = 45 patients with TIPS-induced HE, n = 20 patients received a reduction stent (n = 18) or TIPS occlusion (n = 2) and were differentiated into responders (improvement by at least one HE grade according to the West Haven classification) and non-responders (no improvement).
RESULTS: Older patient age, increased serum creatinine and elevated International Normalized Ratio (INR) immediately after TIPS placement were independent predictors for the development of HE. In 11/20 patients (responders, 55%) undergoing shunt modification, the HE grade was improved compared with nine non-responders (45%), with no relevant recurrence of refractory ascites or variceal bleeding. A high HE grade after TIPS insertion was the only positive predictor of treatment response (p = 0.019). A total of 10/11 responders (91%) survived the 6 months follow-up after modification but only 6/9 non-responders (67%) survived. DISCUSSION: Older patient age as well as an increased serum creatinine and INR after TIPS are potential predictors for the development of HE. TIPS reduction for the treatment of TIPS-induced HE is safe, with particular benefit for patients with pronounced HE.

Entities:  

Keywords:  hepatic encephalopathy; liver cirrhosis; portasystemic shunt; transjugular intrahepatic

Year:  2020        PMID: 32092979     DOI: 10.3390/jcm9020567

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  3 in total

1.  Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure.

Authors:  Hiroaki Takaya; Tadashi Namisaki; Shinya Sato; Kosuke Kaji; Yuki Tsuji; Daisuke Kaya; Yukihisa Fujinaga; Yasuhiko Sawada; Naotaka Shimozato; Hideto Kawaratani; Kei Moriya; Takemi Akahane; Akira Mitoro; Hitoshi Yoshiji
Journal:  J Clin Med       Date:  2020-05-14       Impact factor: 4.241

2.  Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation.

Authors:  Michael Praktiknjo; Jasmin Abu-Omar; Johannes Chang; Daniel Thomas; Christian Jansen; Patrick Kupczyk; Filippo Schepis; Juan Carlos Garcia-Pagan; Manuela Merli; Carsten Meyer; Christian P Strassburg; Claus C Pieper; Jonel Trebicka
Journal:  JHEP Rep       Date:  2021-03-03

3.  A novel score predicts mortality after transjugular intrahepatic portosystemic shunt: MOTS - Modified TIPS Score.

Authors:  Luisa Fürschuß; Florian Rainer; Maria Effenberger; Markus Niederreiter; Rupert H Portugaller; Angela Horvath; Peter Fickert; Vanessa Stadlbauer
Journal:  Liver Int       Date:  2022-04-01       Impact factor: 8.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.